nach oben

Der Nervenarzt

Erschienen in:

08.08.2019 | Opioide | Übersichten

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

verfasst von: Prof. Dr. Michael Soyka, Oliver Pogarell

Erschienen in: Der Nervenarzt | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Opioidsubstitution mit Methadon oder Buprenorphin ist eine anerkannte, weltweit praktizierte First-line-Behandlung der Opioidabhängigkeit. Neben dem in Deutschland bereits verfügbaren wöchentlich oder monatlich subkutan injizierbaren Buprenorphin Depot CAM 2038 (Buvidal®) stehen mit dem monatlich zu applizierenden Depotpräparat RBP-6000 (Sublocade™) und dem 6 Monate wirkenden Buprenorphin-Depot-Implantat (Probuphine™) demnächst wahrscheinlich mehrere langzeitwirksame Buprenorphinformulierungen zur Verfügung. Der bisherige Wissensstand und mögliche Einsatzgebiete dieser Präparate werden diskutiert.

Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F (2017) Pharmacokinetic evaluation of one-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM 2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther 34:560–575CrossRefPubMed

Amato L, Minozzi S, Davoli M, Vecchi S, Ferri MM, Mayet S (2008) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 4:CD5031

Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 9:CD5031

Amato L, Minozzi S, Davoli M, Vecchi S (2011) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 10:CD4147

Barnwal P, Das S, Mondal S, Ramasamy A, Maiti T, Saha A (2017) Probuphine® (buprenorphine implant): a promising candidate in opioid dependence. Ther Adv Psychopharmacol 7:119–134. https://doi.org/10.1177/2045125316681984 CrossRefPubMed

Bundesärztekammer (2017) Richtlinie der Bundesärztekammer zur Durchführung der substitutionsgestützten Behandlung Opioidabhängiger. www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/RL/Substitution.pdf. Zugegriffen: 28. Mai 2019

Center for Behavioral Health Statistics and Quality (CBHSQ) (2016) National survey on drug use and health: detailed tables. Substance abuse and mental health services administrations. SAMHSA, Rockville

Deamer RL, Wilson DR, Clark DS, Prichard JG (2001) Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 20:7–14. https://doi.org/10.1300/J069v20n04_02 CrossRefPubMed

Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N et al (2014) The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 109(8):1320–1333CrossRefPubMed

10.

Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D (2016) A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of Opioid addiction. J Addict Med 10(2):93–103CrossRefPubMed

11.

Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW (2008) A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165(2):179–187CrossRefPubMed

12.

European Agency for the Evaluation of Medical Products (2001). EMEA public statement to suspend the marketing authorisation for Orlaam (levoacetylmethadol) in the European Union. EMEA/8776/01.

13.

Fareed A, Vayalapalli S, Casarella J, Drexler K (2012) Effect of buprenorphine dose on treatment outcome. J Addict Dis 31:8–18CrossRefPubMed

14.

US Food and Drug Administration (2016) Probuphine™ prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204442Orig1s000lbl.pdf

15.

Greenwald MK, Comer SD, Fiellin DA (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend 144:1–11CrossRefPubMed

16.

Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000–2009CrossRefPubMed

17.

Haasen C, Linden M, Tiberg F (2017) Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid disorder. J Subst Abuse Treat 78:22–29CrossRefPubMed

18.

Haight BR, Learned SM, Laffont CM, Fudala J, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbrder C, RB-US-13-0001 Study Investigators (2019) Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 393(10173):778–790. https://doi.org/10.1016/S0140-6736(18)32259-1 CrossRefPubMed

19.

Hser YI, Evans E, Huang D et al (2016) Long-term outcomes after randomization to buprenorphiine/naloxone versus methadone in a multi-site trial. Addiction 111:695–705CrossRefPubMedPubMedCentral

20.

Hser YI, Huang D, Saxon AJ et al (2017) Distinctine trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine+naloxone and methadone. J Addict Med 11:63–69CrossRefPubMedPubMedCentral

21.

Hser YI, Saxon AJ, Huang D et al (2014) Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 109:8–18

22.

Itzoe M, Guarnieri M (2017) New developments in managing opioid addiction: impact of a subdermal buprenorphine implant. Drug Des Devel Ther 11:1429–1437. https://doi.org/10.2147/DDDT.S109331 CrossRefPubMedPubMedCentral

23.

Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750–2755CrossRefPubMed

24.

Kenney SR, Anderson BJ, Bailey GL, Stein MD (2018) Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management. J Subst Abuse Treat 94:55–59. https://doi.org/10.1016/j.jsat.2018.08.011 CrossRefPubMed

25.

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF (2016) Population Pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously Injectable, long-acting, sustained-release formulation of Buprenorphine, for the treatment of Opioid use disorder. J Clin Pharmacol 56:806–815CrossRefPubMed

26.

Ling W, Charuvastra C, Collins JF et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475CrossRefPubMed

27.

Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C (2019) Patient-centered outcomes in participants of a Buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, Multicenter, phase 3 study. J Addict Med. https://doi.org/10.1097/ADM.0000000000000517 CrossRefPubMed

28.

Lofwall MR, Walsh SL (2014) A review of buprenorphine diversion and misuse: the current evidence base and experience from around the world. J Addict Med 8:315–326CrossRefPubMedPubMedCentral

29.

Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S (2018) Weekly and monthly subcutaneous Buprenorhpine depot formulations vs daily Sublingual Burpenorphine with Naloxone for treatment of Opioid use disorder: a randomized clinical trial. JAMA Intern Med 178:764–773CrossRefPubMedPubMedCentral

30.

Mattick RP, Breen C, Kimber J, Davoli M (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev CD002207. https://doi.org/10.1002/14651858.CD002207.pub4 CrossRefPubMed

31.

Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK (2014) A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet 53:813–824CrossRefPubMed

32.

Nasser AF, Greenwald MK, Vince B, Fudala PJ, Twumasi-Ankrah P, Liu Y, Jones JP 3rd, Heidbreder C (2016) Sustained-release Buprenorphine (RBP-6000) blocks the effects of Opioid challenge with Hydromorphone in subjects with Opioid use disorder. J Clin Psychopharmacol 36:18–26. https://doi.org/10.1097/JCP CrossRefPubMedPubMedCentral

33.

Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, Walter M, Seifritz E, Dürsteler KM, Herdener M (2019) One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction 114:103–111. https://doi.org/10.1111/add.14442 CrossRefPubMed

34.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ, PRO-814 Study Group (2016) Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical traial. JAMA 316:282–290CrossRefPubMed

35.

Rosenthal RN, Ling W, Casadonte P et al (2013) Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 108:2141–2149CrossRefPubMedPubMedCentral

36.

Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR (1997) Buprenorphine vs methadone maintenance treatment for concurrent opiod dependence and cocaine abuse. Arch Gen Psychiatry 54:713–720CrossRefPubMed

37.

Schuckit MA (2016) Treatment of opioid-use disorders. N Engl J Med 375:1596–1597CrossRefPubMed

38.

Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA (2019) Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.1406 CrossRefPubMedPubMedCentral

39.

Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H‑U (2017) Six-year outcome of Opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res 23(2):97–105CrossRefPubMed

40.

Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C (2016) Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 35(1):22–35CrossRefPubMed

41.

Volkow ND, Frieden TR, Hyde PS, Cha SS (2014) Medication-Assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med 370:2063–2066CrossRefPubMed

42.

Walsh SL, Comer SD, Lofwall MR et al (2017) Effect of buprenorphine weekly depot (CAM 2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 74:894–902. https://doi.org/10.1001/jamapsychiatry.2017.1874 CrossRefPubMedPubMedCentral

43.

Walter M, Soyka M (2019) Opioide. In: Soyka M et al (Hrsg) Suchtmedizin. Elsevier, München, S 177–202CrossRef

44.

White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 103:37–43. https://doi.org/10.1016/j.drugalcdep.2009.03.008 CrossRefPubMed

45.

Wieneke H, Conrads H, Wolstein J, Breuckmann F, Gastpar M, Erbel R, Scherbaum N (2009) Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation—results from a controlled clinical trial. Eur J Med Res 14:7–12CrossRefPubMedPubMedCentral

46.

Wolstein J, Gastpar M, Finkbeiner T, Heinrich C, Heitkamp R, Poehlke T, Scherbaum N (2009) A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 42:1–8. https://doi.org/10.1055/s-0028-1083818 CrossRefPubMed

Titel: Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution
verfasst von: Prof. Dr. Michael Soyka
Oliver Pogarell
Publikationsdatum: 08.08.2019
Verlag: Springer Medizin
Schlagwörter: Opioide
Opioide
Methadon
Buprenorphin
Erschienen in: Der Nervenarzt / Ausgabe 9/2019
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-019-0783-6

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Erratum zu: Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie

Einstellungen zu Depression und Behandlungsmöglichkeiten von Patienten mit koronarer Herzkrankheit

Hat die Alzheimer-Forschung versagt?

Mitteilungen der DGPPN 9/2019

Zwangsmaßnahmen in psychiatrischen Kliniken – einer von vielen Indikatoren der Behandlungsqualität

Neuroinflammation als Motor der Alzheimer-Erkrankung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein